BioCentury
ARTICLE | Translation in Brief

YABAO GOES BOLD

December 18, 2014 8:00 AM UTC

China-based Yabao Pharmaceutical Group Co. Ltd. and MRC Technology are jointly going where Western pharmas and academics fear to tread with a preclinical partnership to develop compounds against an undisclosed kinase target for Parkinson's disease.

The boldness is on both sides. According to Michael Dalrymple, MRC Technology (MRCT) had trouble signing up Western companies because they saw too much risk in its PD program to invest at this stage. "We couldn't get traction in the West because although companies thought it was interesting, it was too early stage for them," he said...